p.48 抽出テキスト

Circulation. 2019;139:e1082–e1143. DOI: 10.1161/CIR.0000000000000625 June 18/25, 2019 e1129 CLINICAL STATEMENTS AND GUIDELINES

S4.3-28.	 Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added

to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372:2387–97.

4.4 Primary Prevention

S4.4-1.	 Budoff MJ, Young R, Burke G, et al. Ten-year association of coronary artery calcium with atherosclerotic cardiovascular disease (ASCVD) events: the Multi-Ethnic Study of Atherosclerosis (MESA) Eur Heart J. 2018;39:2401–8. S4.4-2.	 Avorn J. The psychology of clinical decision making—implications for medication use. N Engl J Med. 2018;378:689–91. S4.4-3.	 Lloyd-Jones DM, Morris PB, Ballantyne CM, et al. 2016 ACC expert consensus decision pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol. 2016;68:92–125. S4.4-4.	 Lloyd-Jones DM, Morris PB, Ballantyne CM, et al. 2017 focused update of the 2016 ACC expert consensus decision pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. J Am Coll Cardiol. 2017;70:1785–822. S4.4-5.	 Muntner P, Colantonio LD, Cushman M, et al. Validation of the atherosclerotic cardiovascular disease pooled cohort risk equations. JAMA. 2014;311:1406–15. S4.4-6.	 Eckel RH, Jakicic JM, Ard JD, et al. 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129:S76–99. S4.4-7.	 Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. Circulation. 2014;129:S102–38. S4.4-8.	 US Department of Health and Human Services. 2008 Physical Activity Guidelines for Americans. Available at: https://health.gov/ paguidelines/pdf/paguide.pdf. Accessed August 24, 2018. S4.4-9.	 Estruch R, Ros E, Salas-Salvado J, et al. Primary prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med. 2013;368:1279–90. S4.4-10.	 Agriculture. 2015–2020 Dietary Guidelines for Americans. 8th ed. 2015. US Department of Health and Human Services and US Department of, 2015. Available at: http://health.gov/dietary guidelines/2015/guidelines/. Accessed August 24, 2018. S4.4-11.	 Lichtenstein AH, Appel LJ, Brands M, et al. Summary of American Heart Association diet and lifestyle recommendations revision 2006 Arterioscler Thromb Vasc Biol. 2006;26:2186–91. S4.4-12.	 Ginsberg HN, Kris-Etherton P, Dennis B, et al. Effects of reducing dietary saturated fatty acids on plasma lipids and lipoproteins in healthy subjects: the DELTA Study, protocol 1. Arterioscler Thromb Vasc Biol. 1998;18:441–9. S4.4-13.	 Dehghan M, Mente A, Zhang X, et al. Associations of fats and carbohydrate intake with cardiovascular disease and mortality in 18 countries from five continents (PURE): a prospective cohort study. Lancet. 2017;390:2050–62. S4.4-14.	 Chen M, Li Y, Sun Q, et al. Dairy fat and risk of cardiovascular disease in 3 cohorts of US adults. Am J Clin Nutr. 2016;104:1209–17. S4.4-15.	 Loria CM, Liu K, Lewis CE, et al. Early adult risk factor levels and subsequent coronary artery calcification: the CARDIA Study. J Am Coll Cardiol. 2007;49:2013–20. S4.4-16.	 Carr JJ, Jacobs DR Jr, Terry JG, et al. Association of coronary artery calcium in adults aged 32 to 46 years with incident coronary heart disease and death. JAMA Cardiol. 2017;2:391–9. S4.4-17.	 Choosing interventions that are cost effective (WHO-CHOICE): cost-effectiveness thresholds. Geneva, Switzerland: World Health Organization. 2009. S4.4-18.	 Physical Activity Guidelines Advisory Committee report, 2008. To the Secretary of Health and Human Services. Part A: executive summary. Nutr Rev. 2009;67:114–20. S4.4-19.	 Warburton DE, Charlesworth S, Ivey A, et al. A systematic review of

the evidence for Canada’s Physical Activity Guidelines for Adults. Int J Behav Nutr Phys Act. 2010;7:39. S4.4-20.	 Shiroma EJ, Lee IM. Physical activity and cardiovascular health:

lessons learned from epidemiological studies across age, gender, and race/ethnicity. Circulation. 2010;122:743–52. S4.4-21.	 Sattelmair J, Pertman J, Ding EL, et al. Dose response between

physical activity and risk of coronary heart disease: a meta-analysis. Circulation. 2011;124:789–95.

4.4.1 Evaluation and Risk Assessment

4.4.1.1 Essential Process of Risk Assessment

S4.4.1.1-1.	 American College of Cardiology. ASCVD Risk Predictor Plus. Available at: http://tools.acc.org/ASCVD-Risk-Estimator-Plus/#!/ calculate/estimate/. Accessed September 1, 2018. S4.4.1.1-2.	 American Heart Association. ASCVD-Risk-Calculator. Available at: https://professional.heart.org/professional/GuidelinesStatements/ ASCVDRiskCalculator/UCM_457698_ASCVD-Risk-Calculator.jsp. Accessed September 1, 2018. S4.4.1.1-3.	 Karp I, Abrahamowicz M, Bartlett G, et al. Updated risk factor values and the ability of the multivariable risk score to predict coronary heart disease. Am J Epidemiol. 2004;160:707–16. S4.4.1.1-4.	 Pencina MJ, D’Agostino RB Sr, Larson MG, et al. Predicting the

30-year risk of cardiovascular disease: the Framingham Heart Study. Circulation. 2009;119:3078–84.

4.4.1.2 Pooled Cohort Equations

S4.4.1.2-1.	 DeFilippis AP, Young R, Carrubba CJ, et al. An analysis of calibration and discrimination among multiple cardiovascular risk scores in a modern multiethnic cohort. Ann Intern Med. 2015;162:266–75. S4.4.1.2-2.	 Kavousi M, Leening MJ, Nanchen D, et al. Comparison of application of the ACC/AHA guidelines, Adult Treatment Panel III guidelines, and European Society of Cardiology guidelines for cardiovascular disease prevention in a European cohort. JAMA. 2014;311:1416–23. S4.4.1.2-3.	 Wolfson J, Vock DM, Bandyopadhyay S, et al. Use and customization of risk scores for predicting cardiovascular events using electronic health record data. J Am Heart Assoc 2017;6;e003670. S4.4.1.2-4.	 Goff DC Jr, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129:S49–73. S4.4.1.2-5.	 Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129:S1–45. S4.4.1.2-6.	 JBS3 Board. Joint British Societies’ consensus recommendations for the prevention of cardiovascular disease (JBS3) Heart 2014; 100 suppl 2. ii1–67. S4.4.1.2-7.	 Muntner P, Colantonio LD, Cushman M, et al. Validation of the atherosclerotic cardiovascular disease Pooled Cohort risk equations. JAMA. 2014;311:1406–15. S4.4.1.2-8.	 Andersson C, Enserro D, Larson MG, et al. Implications of the US cholesterol guidelines on eligibility for statin therapy in the community: comparison of observed and predicted risks in the Framingham Heart Study Offspring Cohort. J Am Heart Assoc. 2015;4:e001888. S4.4.1.2-9.	 Colantonio LD, Richman JS, Carson AP, et al. Performance of the atherosclerotic cardiovascular disease pooled cohort risk equations by social deprivation status. J Am Heart Assoc. 2017;6:e005676. S4.4.1.2-10.	 Cook NR, Ridker PM. Further insight into the cardiovascular risk calculator: the roles of statins, revascularizations, and underascertainment in the Women’s Health Study. JAMA Intern Med. 2014;174:1964–71. S4.4.1.2-11.	 Dalton JE, Perzynski AT, Zidar DA, et al. Accuracy of cardiovascular risk prediction varies by neighborhood socioeconomic position: a retrospective cohort study. Ann Intern Med. 2017;167:456–64. S4.4.1.2-12.	 Feinstein MJ, Nance RM, Drozd DR, et al. Assessing and refining myocardial infarction risk estimation among patients with human immunodeficiency virus: a study by the Centers for AIDS Research Network of Integrated Clinical Systems. JAMA Cardiol. 2017;2:155–62. S4.4.1.2-13.	 Flueckiger P, Qureshi W, Michos ED, et al. Guideline-based statin/lipid-

lowering therapy eligibility for primary prevention and accuracy of coronary artery calcium and clinical cardiovascular events: the Multi- Ethnic Study of Atherosclerosis (MESA). Clin Cardiol. 2017;40:163–9.

Downloaded from http://ahajournals.org by on October 7, 2026